|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ПсковГУ |
||
Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scaleстатья Исследовательская статья
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 23 января 2026 г.
- Авторы: Shamalov N.A., Chefranova Zh Yu, Yarovaya E.B., Kutsenko V.A., Marskaya N.A., Semenov A.M., Semenov M.P., Ivanov S.V., Romashova Yu A., Markin S.S.
- Журнал: Journal of Thrombosis and Thrombolysis
- Год издания: 2025
- Издательство: Springer Nature
- Местоположение издательства: Switzerland
- DOI: 10.1007/s11239-025-03212-0
- Аннотация: This study aimed to assess the prognostic value of the THRIVE scale in patients aged ≥ 60 years with acute ischemic stroke (AIS) after intravenous thrombolysis with the non-immunogenic staphylokinase compared with alteplase. The post-hoc analysis of FRIDA trial results was performed and enrolled patients aged ≥ 60 years were divided into two groups in accordance with the modified Rankin scale (mRS) score on day 90: good-outcome (mRS 0–2) and poor-outcome (mRS 3–6) groups. The receiver operating characteristic (ROC) curves were compared using Delong test. For all-cause mortality on day 90 the predicted AUC value by the THRIVE scale was 0.8 (0.71–0.9) in the non-immunogenic staphylokinase group and 0.76 (0.66–0.87) in the alteplase group (p = 0.57). For poor outcome, AUC value was 0.73 (0.64–0.82) in the non-immunogenic staphylokinase group and 0.79 (0.71–0.87) in alteplase group (p = 0.36). Thus, our study confirmed the prognostic value of the THRIVE scale to predict the outcomes of the patients aged ≥ 60 years treated with the non-immunogenic staphylokinase.
- Добавил в систему: Иванов Сергей Витальевич